Description
SALICYLIC+ SERUM is a potent skin treatment that combines salicylic acid, l-lactic acid and Azelogicina® to create a dynamic solution for acne-prone skin. SALICYLIC+ SERUM has exfoliating and brightening properties and is appropriate for all skin types especially Rosacea and super sensitive skin! The 2% Azelaic acid derivative in this serum can help to reduce the bumpy skin common with rosacea. Safe and effective way to help keep skin clear from blemishes and can be an alternative to mandelic acid serums.
- 2% Salicylic Acid: an oil-soluble beta hydroxy acid with anti-inflammatory, antiseptic, and exfoliating properties
- 2% L-Lactic Acid: an alpha hydroxy acid with exfoliating, hydrating, and brightening properties
- 2% Azelolicina®: an azelaic acid derivative that has hydrating, firming, and skin brightening properties
Concerns:
Excellent For:
Tips from your Acne Specialist: Salicylic acid paired with Azelaic acid is a potent combination for mild to moderate Acne Rosacea! Rosacea seems to bother a number of people. Rosacea is characterized with symptoms of persistent redness, small papules with clear fluid (pimples that don’t have puss or a core in it, like acne does) and generally affects the middle of the face. Demodex mites are also implicated in making Rosacea worse! (That’s why we love Salicylic Acid for reducing Demodex mite population in the skin). Here is a link to an article about Demodex.
Use: 1 OZ
Directions: Apply 1 pump all over a clean face or affected area.
Ingredients: Aqua (Water), Alcohol Denat., Butylene Glycol, Lactic Acid (L), Potassium Azeloyl Diglycinate, Salicylic Acid, Sodium Hydroxide, Dimethyl Isosorbide, Phenoxyethanol, Hydroxyethylcellulose, Sodium Gluconate, Xanthan Gum, O-cymen-5-OL, Ethylhexylglycerin
Purchase of this item requires supervision by Face Reality Acne Specialist at Skin and Acne Specialist. You will receive an email with instructions on how to use your products from us shortly after purchase!
Contact us for product usage assistance.
Reviews
There are no reviews yet.